Emergency Use Authorization (EUA) Revoked for Bebtelovimab 175 mg, CR 114106

The Food and Drug Administration (FDA) announced on November 30, 2022, that bebtelovimab, 175mg, no longer has Emergency Use Authorization (EAU).    

 

Eli Lilly EUA Monoclonal Antibody COVID-19 Infusion Treatment-bebtelovimab, 175mg 

 

Code 

 

Code Description 

MaineCare Effective Dates 

Q0222 

Injection, bebtelovimab, 175 mg  

08/15/22-11/30/22 

M0222 

Intravenous injection, bebtelovimab, includes injection and post administration monitoring  

08/15/22-11/30/22 

M0223 

Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency  

08/15/22-11/30/22 

 

 If you have questions about bebtelovimab, 175mg, please contact your Provider Relations Specialist. 

Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.

MaineCare logo